However, some of the retrospective comparative studies assessing the prognostic performance of the various multigene assays have reported better predictive performance of the overall and late distant recurrence using PAM50-based ROR score, Breast Cancer Index [11] and EndoPredict (EPclin) [31] over Oncotype DX RS in ER+/HER2- node-negative breast cancer patients [5, 32]. Here, ERBB2 is linked to breast carcinoma.